BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:19 PM
 | 
May 10, 2019
 |  BC Extra  |  Clinical News

FibroGen falls on U.S. safety data for roxadustat

FibroGen lost $9.28 (20%) to $36.39 on Friday after pooled safety analyses of Phase III data of anemia therapy roxadustat raised concerns for investors ahead of planned regulatory filings this fall.

Omega Funds’ Otello Stampacchia told BioCentury that the company's presentation of the data to treat anemia associated with chronic kidney disease lacked clarity. “It is quite likely that this was the result of some negotiation between themselves, AZ and possibly the FDA but it was definitely very confusing.”

Stampacchia added that FibroGen Inc. (NASDAQ:FGEN) could be reluctant to release...

Read the full 429 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >